title: Thyroid cysts treatment with the sclerosing agent Atossiclerol. Long-term (5 to 15 years) follow-up.
abstract: OBJECTIVE
  The aim of this study was to evaluate the long-term efficacy of the sclerosing agent Atossisclerol in the treatment of benign, ecolucent, thyroid cysts.
  
  
  METHODS
  Two groups of cysts, one between 1 and 3 cm and a group smaller than 0.99 mm in maximum diameter (range 0.6-0.99) were considered in the inclusion plan. The localization of the cysts was at lobar level. A limited quantity of Atossisclerol (0.5 to 2%) was injected.
  
  
  RESULTS
  No side effects were noted. After 5 years in the group treated with the sclerosing agent 93% of the cysts were completely disappeared (vs 60% in controls). However the initial target cyst at 5 and years was completely cured in most patients (>80%) treated with the sclerosing agent; at 10 years more than 90% of the original, sclerosed target cysts were not visible. Another control of most of these patients (53/68) at 15 years indicated that sclerosis of the cyst is safe and allow a better occlusion/obliteration (in almost all patients) of the cyst in comparison with aspiration only (slow recurrence in some 25% of the cysts).
  
  
  CONCLUSIONS
  The sclerosing agent can be re-injected in the same patients without significant reaction or clinical problems or immunological reactions.
authors.affiliation: Irvine3 Circulation-Vascular Labs, Department of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy. cardres@abol.it
authors.forename: G
authors.initials: G
authors.lastname: Belcaro
authors.forename: M
authors.initials: M
authors.lastname: Corsi
authors.forename: A
authors.initials: A
authors.lastname: Ricci
authors.forename: R
authors.initials: R
authors.lastname: Cotellese
authors.forename: L
authors.initials: L
authors.lastname: Artese
authors.forename: B
authors.initials: B
authors.lastname: Feragalli
authors.forename: E
authors.initials: E
authors.lastname: Ippolito
mesh_terms: D000328:Adult; D003560:Cysts / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy; D013961:Thyroid Gland / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D016606:Thyroid Nodule / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D012597:Sclerosing Solutions; D011092:Polyethylene Glycols